Baloxavir marboxil
DrugBank ID: DB13997
Summary
| Metric | Value |
|---|---|
| Total Predictions | 50 |
| KG+DL (Dual Validated) | 0 |
| DL Only | 50 |
| KG Only | 0 |
Predictions
| Indication | Score | Source |
|---|---|---|
| influenza, severe, susceptibility to | 0.9956 | DL |
| acquired hemophagocytic lymphohistiocytosis associated with malignant disease | 0.9885 | DL |
| hemophagocytic syndrome associated with an infection | 0.9885 | DL |
| influenza | 0.9865 | DL |
| cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency | 0.9855 | DL |
| Singleton-Merten syndrome | 0.9781 | DL |
| hemophagocytic syndrome | 0.9497 | DL |
| chronic hepatitis C virus infection | 0.9495 | DL |
| hepatitis C virus infection | 0.9326 | DL |
| hepatitis E virus infection | 0.9253 | DL |
| hepatitis A virus infection | 0.9242 | DL |
| Omsk hemorrhagic fever | 0.9200 | DL |
| Kyasanur forest disease | 0.9181 | DL |
| hepatitis, viral, animal | 0.9163 | DL |
| hepatitis B virus infection | 0.8974 | DL |
| pyelonephritis | 0.8798 | DL |
| squamous cell lung carcinoma | 0.8497 | DL |
| mendelian susceptibility to mycobacterial diseases due to complete ISG15 deficiency | 0.8413 | DL |
| A20 haploinsufficiency | 0.8274 | DL |
| immune dysregulation with inflammatory bowel disease | 0.8207 | DL |
| chromhidrosis | 0.8035 | DL |
| X-linked lymphoproliferative disease due to XIAP deficiency | 0.7961 | DL |
| X-linked lymphoproliferative syndrome | 0.7888 | DL |
| X-linked lymphoproliferative disease due to SH2D1A deficiency | 0.7573 | DL |
| obsolete teratozoospermia | 0.7551 | DL |
| primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma | 0.7486 | DL |
| multicentric osteolysis-nodulosis-arthropathy spectrum | 0.7242 | DL |
| singleton-Merten dysplasia | 0.7232 | DL |
| primary cutaneous peripheral T-cell lymphoma not otherwise specified | 0.7227 | DL |
| hemophagocytic lymphohistiocytosis | 0.7198 | DL |
| immunodeficiency syndrome with abnormal pigmentation | 0.7117 | DL |
| amebiasis | 0.7063 | DL |
| normophosphatemic familial tumoral calcinosis | 0.6985 | DL |
| Plasmodium falciparum malaria | 0.6887 | DL |
| aplasia cutis congenita | 0.6841 | DL |
| chronic hepatitis B virus infection | 0.6827 | DL |
| glottis verrucous carcinoma | 0.6808 | DL |
| hypoproteinemia, hypercatabolic | 0.6798 | DL |
| dermo-odonto dysplasia | 0.6791 | DL |
| peripheral T-cell lymphoma, not otherwise specified | 0.6783 | DL |
| supraglottis verrucous carcinoma | 0.6739 | DL |
| MHC class I deficiency | 0.6713 | DL |
| hypohidrotic ectodermal dysplasia-hypothyroidism-ciliary dyskinesia syndrome | 0.6712 | DL |
| X-linked hypohidrotic ectodermal dysplasia | 0.6687 | DL |
| focal facial dermal dysplasia | 0.6657 | DL |
| lymphangiomyoma | 0.6647 | DL |
| benign PEComa | 0.6646 | DL |
| uterine corpus perivascular epithelioid cell tumor | 0.6588 | DL |
| ectodermal dysplasia, trichoodontoonychial type | 0.6507 | DL |
| primary cutaneous gamma/delta-positive T-cell lymphoma | 0.6440 | DL |
External Links
Disclaimer
Predictions are for research purposes only and do not constitute medical advice.
Predictions are for research purposes only and do not constitute medical advice.